The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston ...

This was due to continued investments by GSK for launching new products and supporting the global market expansion of its existing marketed drugs. Core research and development expenses rose 2% to ...

GSK on Wednesday said it was "well positioned" to absorb potential U.S. pharmaceutical tariffs, citing AI-driven cost cuts ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

(RTTNews) - British drug maker GSK plc (GSK.L, GSK ... authorisation in the world was by the UK Medicines and Healthcare products Regulatory Agency (MHRA) last month. Multiple myeloma is the ...

GSK reports financial figures under three segments — Specialty Medicines, Vaccines and General Medicines. In the first quarter, higher sales of newer products like Cabenuva, Juluca, Dovato ...

GSK is focusing on expanding newer products, particularly in infectious diseases, to offset declining sales from top drugs and vaccines as demand slows and competition increases. GSK is also ...